Nanopublications

@prefix this: <http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84> .
@prefix sub: <http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84#> .
@prefix drugbank: <http://identifiers.org/drugbank/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix pav: <http://purl.org/pav/> .
@prefix infores: <https://w3id.org/biolink/infores/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix ntemplate: <https://w3id.org/np/o/ntemplate/> .
@prefix orcid: <https://orcid.org/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix pmid: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix ncit: <http://purl.obolibrary.org/obo/NCIT_> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubInfo ;
    a np:Nanopublication .
}

sub:assertion {
  drugbank:DB00334 a biolink:Drug ;
    rdfs:label "Olanzapine" ;
    biolink:category biolink:Drug .
  <http://purl.obolibrary.org/obo/DOID_1574> a biolink:Disease ;
    rdfs:label "alcohol use disorder" ;
    biolink:category biolink:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_1574> ;
    rdf:predicate biolink:treats ;
    rdf:subject drugbank:DB00334 ;
    a biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    rdfs:label "Olanzapine was FDA approved for the treatment of schizophrenia and bipolar disorder only. It is an atypical antagonist of D2 and D4 receptors which determines a decrease in craving for alcohol. The DRD4 gene of dopamine presents a VNTR polymorphism, with a number of repetitions that varies from 2 to 11 which allows for the division of individuals in two subgroups: those with a number of repetitions between 2 and 6, classified as DRD4 S and those with more than 7 repetitions, classified as DRD4 L. Association studies between this variation and AUD have showed that individuals who carry the L allele exhibit greater craving after alcohol intake,50. Another study has investigated the association olanzapine-DRD4 showing that olanzapine reduces craving to the L allele carriers only, while no benefits were observed in S allele carriers." ;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory ;
    biolink:category biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    biolink:has_population_context sub:context ;
    biolink:publications pmid:29912214 ;
    biolink:relation ncit:C94303 .
  sub:context a biolink:Cohort ;
    rdfs:label "adults" ;
    biolink:category biolink:Cohort .
}

sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 .
}

sub:pubInfo {
  sub:sig npx:hasAlgorithm "RSA" ;
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB" ;
    npx:hasSignature "EZH5DT4K3l3uk6H65DHWAFQwIG+q31cWFOWWvUTRFQEbfkP87pLflbnQY7oS7uK9Y2L1/1z7o1EAR8ztBHhZBiyhtO0V2nHq+BNRb4bTQw5R6rSh7tLcxWc0nWl4tfQKmTRJFa/E1ZlhMXlourWMY1+X7ekIYjn7T3WtuTCDpnQ=" ;
    npx:hasSignatureTarget this: .
  this: prov:generatedAtTime "2022-09-16T11:54:35.529379"^^xsd:dateTime ;
    prov:wasAttributedTo orcid:0000-0002-1501-1082 ;
    ntemplate:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
  biolink: pav:version "2.3.0" .
}